CTOs on the Move

Aoxing Pharmaceutical

www.aoxingpharma.com

 
Aoxing Pharmaceutical Company, Inc (NYSE AMEX: AXN) is registered in Florida in US and it is a specialty pharmaceutical company which specializes in research, development, manufacturing and distribution of a variety of narcotics and pain-management products and drug-relief medicine. Aoxing has its office in Jersey city and headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliance partnerships ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Cassini Technologies

Driven by curiosity and love of science Cassini has been dedicated to push the boundaries of corneal diagnostics solutions ✓ Advised by top surgeons

BlueSprig

Our mission is simple: we are focused on changing the world for children with autism. Learn more about our ABA Services.

Pharmacy Data Management

Pharmacy Data Management is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thermal Fisher Scientific Remel Products Inc

Thermal Fisher Scientific Remel Products Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.